The low allelic frequency of KRAS mutations is explicable by their heterozygous nature and the robust inflammatory responses KRAS‐mutant tumors generate (Agalioti et al, 2017; Marazioti et al, 2018) and is not limiting their driver capabilities in other tumor types (Abbosh et al, 2017; Jamal‐Hanjani et al, 2017; Li et al, 2020). The gene discussed is KRAS; the disease is neoplasm.